Sandoz Group AGSDZXF 18 EBITDA Margin % is 18.55% as of Dec. 2025, which is 41% above its 10-year median of 13.14. GuruFocus rates SDZXF with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Sandoz Group AG ranks better than 63.35% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sandoz Group AG's EBITDA for the
six
months ended in Dec. 2025 was $1,093 Mil. Sandoz Group AG's Revenue for the
six
months ended in Dec. 2025 was $5,892 Mil. Therefore, Sandoz Group AG's EBITDA margin for the quarter that ended in Dec. 2025 was 18.55%.
Sandoz Group AG (OTCPK:SDZXF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sandoz Group AG EBITDA Margin % Related Terms
Sandoz Group AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SDZXF vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (SDZXF) has a EBITDA Margin % of 18.55% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sandoz Group AG and its competitors. This is 41% above median its historical median of 13.14. Over the past decade, Sandoz Group AG's EBITDA Margin % has ranged from 7.15 to 18.09. According to the industry distribution chart, Sandoz Group AG ranks #350 out of 955 companies in the Drug Manufacturers industry, placing it in the top 36.6%.
Is Sandoz Group AG's EBITDA Margin % too high?
Sandoz Group AG's current EBITDA Margin % of 18.55% is 41% above median its 10-year median of 13.14. Over the past 10 years, this metric has ranged from a low of 7.15 to a high of 18.09. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Sandoz Group AG's value of 18.55% is 49.1% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #350 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #350 out of 955 companies for EBITDA Margin %. This puts Sandoz Group AG in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Sandoz Group AG's value of 18.55% is 49.1% above this benchmark. Historically, Sandoz Group AG's own EBITDA Margin % has ranged from 7.15 to 18.09 over the past decade. While the company's 10-year median is 13.14 vs. the industry median of 12.44, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current EBITDA Margin % of 18.55% is 49.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current EBITDA Margin % is 18.55%, which is 41% above median its own 10-year median of 13.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current EBITDA Margin % of 18.55%. The current EBITDA Margin % is 18.55%, which is 41% above median its 10-year median of 13.14 and 49.1% above the Drug Manufacturers industry median of 12.44. Sandoz Group AG's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current EBITDA Margin % is 18.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
18GF Score
Get the complete analysis for SDZXF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDZXF has been successfully added to your 